Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Collaborators

Mark Middleton - Head, Department of OncologyMark Middleton

Head, Department of Oncology

 

DavidKerrrdm.jpgDavid Kerr

Professor of Cancer Medicine, RDM

 

FRS FMedSci Ian Tomlinson - Professor of Cancer GeneticsIan Tomlinson

Professor of Cancer Genetics

 

Lizzy Smyth - Honorary Clinical ResearcherLizzy Smyth

Honorary Clinical Researcher

 

BrianNicholson.jpgBrian Nicholson

Associate Professor, NDPCH

 

Yoshiaki Nakamura

Royal Society Wolfson Visiting Fellow

Biography

Dr Yoshiaki Nakamura trained in Medicine at Osaka University and obtained his PhD from Keio University. His clinical and research interests focus on gastrointestinal cancer, liquid biopsy, precision oncology, and early cancer detection. He has led multiple nationwide studies, including SCRUM-Japan and CIRCULATE-Japan, pioneering the clinical use of circulating tumour DNA (ctDNA) for precision medicine and minimal residual disease (MRD) monitoring. Dr Nakamura has served as Principal Investigator on numerous clinical and translational trials that contributed to new drug and companion diagnostic approvals in Japan. 

Research Summary

Dr Nakamura’s research focuses on translating liquid biopsy technologies into clinical practice for precision oncology and early cancer detection. His work integrates circulating tumour DNA (ctDNA) analysis for minimal residual disease (MRD) and multi-cancer early detection (MCED) with artificial intelligence-driven histopathological and genomic modelling. Dr Nakamura aims to build large-scale, data-driven frameworks that bridge clinical trials, molecular profiling, and digital health innovation.